Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $204000.0.

  • Bicycle Therapeutics' Other Accumulated Expenses fell 4887.22% to $204000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $204000.0, marking a year-over-year decrease of 4887.22%. This contributed to the annual value of $297000.0 for FY2024, which is 1556.42% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Other Accumulated Expenses of $204000.0 as of Q3 2025, which was down 4887.22% from $236000.0 recorded in Q2 2025.
  • Bicycle Therapeutics' Other Accumulated Expenses' 5-year high stood at $1.5 million during Q4 2022, with a 5-year trough of $64000.0 in Q2 2021.
  • In the last 5 years, Bicycle Therapeutics' Other Accumulated Expenses had a median value of $309000.0 in 2025 and averaged $472789.5.
  • In the last 5 years, Bicycle Therapeutics' Other Accumulated Expenses soared by 139687.5% in 2022 and then crashed by 8254.08% in 2023.
  • Over the past 5 years, Bicycle Therapeutics' Other Accumulated Expenses (Quarter) stood at $570000.0 in 2021, then skyrocketed by 158.25% to $1.5 million in 2022, then plummeted by 82.54% to $257000.0 in 2023, then grew by 15.56% to $297000.0 in 2024, then crashed by 31.31% to $204000.0 in 2025.
  • Its Other Accumulated Expenses was $204000.0 in Q3 2025, compared to $236000.0 in Q2 2025 and $309000.0 in Q1 2025.